65,437 trials
Acne Vulgaris
Primary: Expert Grader Assessment - Erythema — 0.0; 0.0; 0.4; 2.0 Scores on a Scale
Multiple Myeloma · Lymphoma
Primary: Average Overall Survival Time — 3 years
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 5.1; 6.2 months — p=0.2804
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088
Chronic Migraine
Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…
HIV Infections
Primary: Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping…
Osteoarthritis, Knee · Musculoskeletal Diseases
Primary: Change From Baseline in Knee Pain Over the Course of the 26-week Initial Treatment Period As Measured by Participants Using the Western Ontario and McMaster Universities…
Transposition of Great Vessels · Congenital Heart Disease
Primary: Maximum Decline in Measured Cardiac Output — 0.68; 0.29 L/min/m2
Adenocarcinoma
Primary: Overall Survival — 12.1; 10.1 months
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation — 30.7 percentage of participants
Toothache
Primary: Percentage of Participants With a Response — 70.4; 80.7; 87.3 Percentage of participants — p=<0.001
Human Immunodeficiency Virus
Primary: Number of Patients With Adverse Drug Reactions (ADRs) — 2; 5; 1; 0 participants
Chronic Rhinosinusitis
Primary: Number of Participants in Compliance With Medical Recommendations — 20; 10 participants
Rheumatoid Arthritis
Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects
Acute Lymphoblastic Leukemia
Primary: MTD of VSLI — 2.25 mg/m2